Gastrointestinal Stromal Tumors

INTRIGUE: Final Overall Survival Analysis of Ripretinib Compared With Sunitinib in Patients With GIST
Final INTRIGUE trial data highlight outcomes of ripretinib vs sunitinib in patients with GIST.
Advertisement

Video Insights

Advertisement